Equities

Revolution Medicines Inc

Revolution Medicines Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)60.44
  • Today's Change1.34 / 2.27%
  • Shares traded1.81m
  • 1 Year change+185.36%
  • Beta1.4178
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

  • Revenue in USD (TTM)742.00k
  • Net income in USD-567.06m
  • Incorporated2014
  • Employees490.00
  • Location
    Revolution Medicines Inc700 Saginaw DrREDWOOD CITY 94063-4752United StatesUSA
  • Phone+1 (415) 766-3638
  • Fax+1 (302) 636-5454
  • Websitehttps://www.revmed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Legend Biotech Corp (ADR)455.99m-285.01m7.38bn2.20k--6.33--16.18-1.57-1.572.516.330.244610.6332.42253,328.30-15.29-37.71-17.63-47.1960.28---62.50-286.514.78--0.2263--143.7042.15-16.11--1.57--
Viking Therapeutics Inc0.00-99.15m7.63bn33.00--8.37-----0.937-0.9370.008.180.00----0.00-15.02-21.91-15.47-23.04------------0.00-------24.73------
Madrigal Pharmaceuticals Inc76.81m-518.67m7.65bn376.00--9.84--99.58-25.07-25.073.7135.640.1172----204,289.90-79.11-62.09-100.35-74.8196.37---675.24--5.93--0.1309-------26.50--132.01--
Exact Sciences Corp2.69bn-214.04m9.53bn6.50k--2.975,226.403.54-1.17-1.1714.7017.350.40895.4011.60414,204.30-3.25-9.71-3.58-10.6072.9674.10-7.95-28.211.93--0.4459--19.9340.6367.26---3.71--
Revolution Medicines Inc742.00k-567.06m10.17bn490.00--6.47--13,702.40-3.59-3.590.00479.340.0005--4.801,962.96-41.28-29.76-44.46-32.59-----76,423.31-606.93----0.00---67.27-10.50-75.46--38.82--
Exelixis Inc2.08bn466.92m10.35bn1.31k23.104.5520.934.971.571.576.927.960.70123.398.041,589,006.0015.738.8618.089.9196.2596.3022.4315.433.88--0.000.0013.6016.4713.98-21.343.98--
Charles River Lbrtrs ntrntl Inc4.06bn413.08m11.01bn20.00k26.892.9114.342.718.018.0178.6373.970.52038.275.23203,045.805.486.466.337.6235.9336.9910.5411.581.144.960.37840.003.8612.75-2.3916.6917.86--
Medpace Holdings Inc2.07bn365.57m11.28bn5.90k31.7712.7628.595.4511.4211.4264.7028.421.16--6.85350,994.3020.4813.9443.5123.1829.6928.8417.6615.23----0.00--29.1721.7615.2631.1717.99--
Tempus AI Inc640.44m-800.71m11.38bn2.30k--213.26--17.78-8.29-8.294.440.3459----------------53.18---116.06--2.55-14.950.891--65.85--20.35------
Sarepta Therapeutics Inc1.64bn121.85m11.62bn1.31k100.009.5172.387.081.221.2216.3012.790.4890.57034.351,248,362.003.63-21.634.38-25.7585.9286.657.43-77.053.03--0.5013--33.2632.8023.81--6.30--
BIO-TECHNE Corp1.17bn150.68m12.07bn3.10k80.805.6446.0610.300.94020.94027.2913.460.42672.155.47377,930.005.499.425.7710.0465.9367.2912.8621.413.2618.070.12322.791.9710.17-41.0711.8619.870.00
Neurocrine Biosciences, Inc.2.24bn385.90m12.73bn1.70k33.674.6830.935.683.733.7321.6726.870.70270.89014.991,602,000.0012.099.7714.6712.1998.5298.5117.2114.794.2610.280.00--26.7633.1361.6263.902.67--
Insmed Inc342.96m-864.29m13.16bn912.00--27.21--38.36-5.56-5.562.212.700.20310.88488.81376,050.40-51.17-40.96-59.16-46.8877.2577.99-252.01-212.925.99-18.410.6702--24.3998.78-55.66---2.15--
Vaxcyte Inc0.00-507.65m13.29bn254.00--3.88-----4.55-4.550.0027.470.00----0.00-20.08-34.22-20.95-37.21------------0.00-------80.00--107.28--
Data as of Nov 08 2024. Currency figures normalised to Revolution Medicines Inc's reporting currency: US Dollar USD

Institutional shareholders

48.29%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202414.03m8.40%
Wellington Management Co. LLPas of 30 Sep 202411.40m6.83%
BlackRock Fund Advisorsas of 30 Jun 202410.90m6.53%
Farallon Capital Management LLCas of 30 Jun 20249.76m5.84%
Baker Bros. Advisors LPas of 30 Jun 20247.57m4.53%
BVF Partners LPas of 30 Jun 20245.98m3.58%
Fidelity Management & Research Co. LLCas of 30 Jun 20245.62m3.37%
Paradigm BioCapital Advisors LPas of 30 Jun 20245.26m3.15%
SSgA Funds Management, Inc.as of 30 Jun 20245.07m3.04%
T. Rowe Price Associates, Inc. (IM)as of 30 Jun 20245.06m3.03%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.